Kazazian Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Kazazian Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,901	Closed	-$393K	–	69
2018 Q4	$393K	Buy	3,901 +1,395	+56%	+$145K	0.53%	33
2018 Q3	$317K	Sell	2,506 -2,506	-50%	-$265K	0.3%	64
2018 Q2	$421K	Sell	5,012 -192	-4%	-$14.1K	0.39%	52
2018 Q1	$320K	Hold	5,204	–	–	0.34%	60
2017 Q4	$304K	Sell	5,204 -3,462	-40%	-$218K	0.31%	63
2017 Q3	$503K	Buy	+8,666	New	+$933K	0.62%	36

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Kazazian Asset Management's ICPT Position: Q1 2019 in Review

Kazazian Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2019, closing a stake of 3,901 shares — an estimated $393K sold.

Kazazian Asset Management first reported a position in ICPT in Q3 2017 and held it in 6 quarters. The position peaked at $503K in Q3 2017. 202 funds tracked by Wall St. Rank hold ICPT as of Q1 2019.

Kazazian Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Kazazian Asset Management sold 3,901 Intercept Pharmaceuticals, Inc. shares in Q1 2019, an estimated $393K.
Kazazian Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2017 and held it in 6 quarters.
Kazazian Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $503K in Q3 2017.
202 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2019.

Based on Kazazian Asset Management's 13F filing for Q1 2019, filed 15 May 2019.